Selected research
Industry Research
Icatibant Acetate Injection Industry Research Report 2026
Market perspective
The global Icatibant Acetate Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Icatibant Acetate Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Icatibant Acetate Injection is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Icatibant Acetate Injection is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Icatibant Acetate Injection include Cipla, Eugia Pharma Specialities, Fresenius Kabi, Glenmark Pharmaceuticals, Chengdu Shengnuo Biology Pharmacy, Jiangsu Hengrui Pharmaceuticals, Sandoz and Takeda Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Icatibant Acetate Injection market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Icatibant Acetate Injection Market by Company
Cipla
Eugia Pharma Specialities
Fresenius Kabi
Glenmark Pharmaceuticals
Chengdu Shengnuo Biology Pharmacy
Jiangsu Hengrui Pharmaceuticals
Sandoz
Takeda Pharmaceuticals
Icatibant Acetate Injection Segment by Type
Original Drug
Generic Drug
Icatibant Acetate Injection Segment by Application
Hospital and Clinic
Pharmacy
Other
Icatibant Acetate Injection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Icatibant Acetate Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Icatibant Acetate Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Icatibant Acetate Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Icatibant Acetate Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Icatibant Acetate Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Icatibant Acetate Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Original Drug
- Generic Drug
Applications
- Hospital and Clinic
- Pharmacy
- Other
Companies covered
- Cipla
- Eugia Pharma Specialities
- Fresenius Kabi
- Glenmark Pharmaceuticals
- Chengdu Shengnuo Biology Pharmacy
- Jiangsu Hengrui Pharmaceuticals
- Sandoz
- Takeda Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Icatibant Acetate Injection Market Size (2021-2032)
- 2.2.2 Global Icatibant Acetate Injection Sales (2021-2032)
- 2.2.3 Global Icatibant Acetate Injection Market Average Price (2021-2032)
- 2.3 Icatibant Acetate Injection by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Original Drug
- 2.3.3 Generic Drug
- 2.4 Icatibant Acetate Injection by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital and Clinic
- 2.4.3 Pharmacy
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Icatibant Acetate Injection Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Icatibant Acetate Injection Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Icatibant Acetate Injection Revenue of Manufacturers (2021-2026)
- 3.4 Global Icatibant Acetate Injection Average Price by Manufacturers (2021-2026)
- 3.5 Global Icatibant Acetate Injection Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Icatibant Acetate Injection, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Icatibant Acetate Injection, Product Type & Application
- 3.8 Global Manufacturers of Icatibant Acetate Injection, Established Date
- 3.9 Global Icatibant Acetate Injection Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Cipla
- 4.1.1 Cipla Company Information
- 4.1.2 Cipla Business Overview
- 4.1.3 Cipla Icatibant Acetate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Cipla Icatibant Acetate Injection Product Portfolio
- 4.1.5 Cipla Recent Developments
- 4.2 Eugia Pharma Specialities
- 4.2.1 Eugia Pharma Specialities Company Information
- 4.2.2 Eugia Pharma Specialities Business Overview
- 4.2.3 Eugia Pharma Specialities Icatibant Acetate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Eugia Pharma Specialities Icatibant Acetate Injection Product Portfolio
- 4.2.5 Eugia Pharma Specialities Recent Developments
- 4.3 Fresenius Kabi
- 4.3.1 Fresenius Kabi Company Information
- 4.3.2 Fresenius Kabi Business Overview
- 4.3.3 Fresenius Kabi Icatibant Acetate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Fresenius Kabi Icatibant Acetate Injection Product Portfolio
- 4.3.5 Fresenius Kabi Recent Developments
- 4.4 Glenmark Pharmaceuticals
- 4.4.1 Glenmark Pharmaceuticals Company Information
- 4.4.2 Glenmark Pharmaceuticals Business Overview
- 4.4.3 Glenmark Pharmaceuticals Icatibant Acetate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Glenmark Pharmaceuticals Icatibant Acetate Injection Product Portfolio
- 4.4.5 Glenmark Pharmaceuticals Recent Developments
- 4.5 Chengdu Shengnuo Biology Pharmacy
- 4.5.1 Chengdu Shengnuo Biology Pharmacy Company Information
- 4.5.2 Chengdu Shengnuo Biology Pharmacy Business Overview
- 4.5.3 Chengdu Shengnuo Biology Pharmacy Icatibant Acetate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Chengdu Shengnuo Biology Pharmacy Icatibant Acetate Injection Product Portfolio
- 4.5.5 Chengdu Shengnuo Biology Pharmacy Recent Developments
- 4.6 Jiangsu Hengrui Pharmaceuticals
- 4.6.1 Jiangsu Hengrui Pharmaceuticals Company Information
- 4.6.2 Jiangsu Hengrui Pharmaceuticals Business Overview
- 4.6.3 Jiangsu Hengrui Pharmaceuticals Icatibant Acetate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Jiangsu Hengrui Pharmaceuticals Icatibant Acetate Injection Product Portfolio
- 4.6.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
- 4.7 Sandoz
- 4.7.1 Sandoz Company Information
- 4.7.2 Sandoz Business Overview
- 4.7.3 Sandoz Icatibant Acetate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sandoz Icatibant Acetate Injection Product Portfolio
- 4.7.5 Sandoz Recent Developments
- 4.8 Takeda Pharmaceuticals
- 4.8.1 Takeda Pharmaceuticals Company Information
- 4.8.2 Takeda Pharmaceuticals Business Overview
- 4.8.3 Takeda Pharmaceuticals Icatibant Acetate Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Takeda Pharmaceuticals Icatibant Acetate Injection Product Portfolio
- 4.8.5 Takeda Pharmaceuticals Recent Developments
5 Global Icatibant Acetate Injection Market Scenario by Region
- 5.1 Global Icatibant Acetate Injection Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Icatibant Acetate Injection Sales by Region: 2021-2032
- 5.2.1 Global Icatibant Acetate Injection Sales by Region: 2021-2026
- 5.2.2 Global Icatibant Acetate Injection Sales by Region: 2027-2032
- 5.3 Global Icatibant Acetate Injection Revenue by Region: 2021-2032
- 5.3.1 Global Icatibant Acetate Injection Revenue by Region: 2021-2026
- 5.3.2 Global Icatibant Acetate Injection Revenue by Region: 2027-2032
- 5.4 North America Icatibant Acetate Injection Market Facts & Figures by Country
- 5.4.1 North America Icatibant Acetate Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Icatibant Acetate Injection Sales by Country (2021-2032)
- 5.4.3 North America Icatibant Acetate Injection Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Icatibant Acetate Injection Market Facts & Figures by Country
- 5.5.1 Europe Icatibant Acetate Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Icatibant Acetate Injection Sales by Country (2021-2032)
- 5.5.3 Europe Icatibant Acetate Injection Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Icatibant Acetate Injection Market Facts & Figures by Country
- 5.6.1 Asia Pacific Icatibant Acetate Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Icatibant Acetate Injection Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Icatibant Acetate Injection Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Icatibant Acetate Injection Market Facts & Figures by Country
- 5.7.1 South America Icatibant Acetate Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Icatibant Acetate Injection Sales by Country (2021-2032)
- 5.7.3 South America Icatibant Acetate Injection Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Icatibant Acetate Injection Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Icatibant Acetate Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Icatibant Acetate Injection Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Icatibant Acetate Injection Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Icatibant Acetate Injection Sales by Type (2021-2032)
- 6.1.1 Global Icatibant Acetate Injection Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Icatibant Acetate Injection Sales Market Share by Type (2021-2032)
- 6.2 Global Icatibant Acetate Injection Revenue by Type (2021-2032)
- 6.2.1 Global Icatibant Acetate Injection Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Icatibant Acetate Injection Revenue Market Share by Type (2021-2032)
- 6.3 Global Icatibant Acetate Injection Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Icatibant Acetate Injection Sales by Application (2021-2032)
- 7.1.1 Global Icatibant Acetate Injection Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Icatibant Acetate Injection Sales Market Share by Application (2021-2032)
- 7.2 Global Icatibant Acetate Injection Revenue by Application (2021-2032)
- 7.2.1 Global Icatibant Acetate Injection Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Icatibant Acetate Injection Revenue Market Share by Application (2021-2032)
- 7.3 Global Icatibant Acetate Injection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Icatibant Acetate Injection Value Chain Analysis
- 8.1.1 Icatibant Acetate Injection Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Icatibant Acetate Injection Production Mode & Process
- 8.2 Icatibant Acetate Injection Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Icatibant Acetate Injection Distributors
- 8.2.3 Icatibant Acetate Injection Customers
9 Global Icatibant Acetate Injection Analyzing Market Dynamics
- 9.1 Icatibant Acetate Injection Industry Trends
- 9.2 Icatibant Acetate Injection Industry Drivers
- 9.3 Icatibant Acetate Injection Industry Opportunities and Challenges
- 9.4 Icatibant Acetate Injection Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst